Aimovig (Erenumab PFS) 70mg/ml

Aimovig (erenumab) is a prescription injection for migraine prevention in adults. This 70mg/ml prefilled syringe offers targeted CGRP receptor blockade to reduce migraine frequency. Suitable for self-administration at home under medical guidance. Store between 2-8°C to maintain potency.

Strength

70mg/ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Novartis

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Aimovig is used to prevent migraine headaches in adults, including those with episodic or chronic migraine. It works by blocking calcitonin gene-related peptide receptors involved in migraine pain pathways. People often ask what Aimovig is used for when exploring preventive treatments for frequent migraine attacks.

Side Effects

Users may notice fewer migraine days per month after starting Aimovig therapy. Some report reduced intensity of remaining migraines when they occur. The medication is designed for ongoing use to build preventive benefits over time.

Precautions & Warnings

Keep Aimovig refrigerated between 2-8°C and protect from light. Allow the prefilled syringe to reach room temperature for 30 minutes before use. Do not shake the syringe or expose to extreme temperatures. Dispose of used syringes in a sharps container as directed.

Avoid Interactions

Aimovig has minimal known drug interactions due to its targeted mechanism. No specific food or alcohol restrictions are required. Always inform your healthcare provider about all medications being taken before starting Aimovig therapy.

Frequently Asked Questions

Some patients notice effects within the first few weeks, while others may take up to 3 months to experience the full preventive benefit.

Consult your healthcare provider about Aimovig use during pregnancy, as safety data in pregnant women is limited.

Aimovig is typically administered once monthly as a subcutaneous injection under the skin of the abdomen, thigh, or upper arm.

Contact your healthcare provider for guidance if a dose is missed; do not take two doses close together to make up for a missed one.

Weight changes are not commonly reported side effects of Aimovig therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.